Loading...

OraSure Technologies

Nasdaq:OSUR
Snowflake Description

Adequate balance sheet and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
OSUR
Nasdaq
$549M
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. The last earnings update was 41 days ago. More info.


Add to Portfolio Compare Print
  • OraSure Technologies has significant price volatility in the past 3 months.
OSUR Share Price and Events
7 Day Returns
3.9%
NasdaqGS:OSUR
1.5%
US Medical Equipment
1.2%
US Market
1 Year Returns
-49.5%
NasdaqGS:OSUR
14.6%
US Medical Equipment
2.3%
US Market
OSUR Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
OraSure Technologies (OSUR) 3.9% 4.7% -23.5% -49.5% 30.6% 2.3%
US Medical Equipment 1.5% 7.4% 2.7% 14.6% 63.8% 98.7%
US Market 1.2% 2% 2% 2.3% 37.9% 39.8%
1 Year Return vs Industry and Market
  • OSUR underperformed the Medical Equipment industry which returned 14.6% over the past year.
  • OSUR underperformed the Market in United States of America which returned 2.3% over the past year.
Price Volatility
OSUR
Industry
5yr Volatility vs Market

Value

 Is OraSure Technologies undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of OraSure Technologies to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for OraSure Technologies.

NasdaqGS:OSUR Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 3 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.1%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGS:OSUR
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.85
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.852 (1 + (1- 21%) (1%))
0.905
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.91
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.905 * 5.96%)
8.13%

Discounted Cash Flow Calculation for NasdaqGS:OSUR using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for OraSure Technologies is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGS:OSUR DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.13%)
2019 25.40 Analyst x1 23.49
2020 26.60 Analyst x1 22.75
2021 27.68 Est @ 4.04% 21.89
2022 28.69 Est @ 3.65% 20.99
2023 29.65 Est @ 3.37% 20.06
2024 30.60 Est @ 3.18% 19.15
2025 31.53 Est @ 3.05% 18.25
2026 32.46 Est @ 2.95% 17.37
2027 33.39 Est @ 2.88% 16.53
2028 34.34 Est @ 2.84% 15.72
Present value of next 10 years cash flows $196.22
NasdaqGS:OSUR DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $34.34 × (1 + 2.73%) ÷ (8.13% – 2.73%)
$653.92
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $653.92 ÷ (1 + 8.13%)10
$299.41
NasdaqGS:OSUR Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $196.22 + $299.41
$495.62
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $495.62 / 62.05
$7.99
NasdaqGS:OSUR Discount to Share Price
Calculation Result
Value per share (USD) From above. $7.99
Current discount Discount to share price of $8.84
= -1 x ($8.84 - $7.99) / $7.99
-10.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of OraSure Technologies is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for OraSure Technologies's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are OraSure Technologies's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:OSUR PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $0.31
NasdaqGS:OSUR Share Price ** NasdaqGS (2019-06-19) in USD $8.84
United States of America Medical Equipment Industry PE Ratio Median Figure of 64 Publicly-Listed Medical Equipment Companies 41.06x
United States of America Market PE Ratio Median Figure of 3,092 Publicly-Listed Companies 17.87x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of OraSure Technologies.

NasdaqGS:OSUR PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:OSUR Share Price ÷ EPS (both in USD)

= 8.84 ÷ 0.31

28.13x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • OraSure Technologies is good value based on earnings compared to the US Medical Equipment industry average.
  • OraSure Technologies is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does OraSure Technologies's expected growth come at a high price?
Raw Data
NasdaqGS:OSUR PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 28.13x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
17.7%per year
United States of America Medical Equipment Industry PEG Ratio Median Figure of 55 Publicly-Listed Medical Equipment Companies 2.3x
United States of America Market PEG Ratio Median Figure of 2,128 Publicly-Listed Companies 1.53x

*Line of best fit is calculated by linear regression .

NasdaqGS:OSUR PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 28.13x ÷ 17.7%

1.59x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • OraSure Technologies is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on OraSure Technologies's assets?
Raw Data
NasdaqGS:OSUR PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $4.55
NasdaqGS:OSUR Share Price * NasdaqGS (2019-06-19) in USD $8.84
United States of America Medical Equipment Industry PB Ratio Median Figure of 183 Publicly-Listed Medical Equipment Companies 4.44x
United States of America Market PB Ratio Median Figure of 5,246 Publicly-Listed Companies 1.8x
NasdaqGS:OSUR PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:OSUR Share Price ÷ Book Value per Share (both in USD)

= 8.84 ÷ 4.55

1.94x

* Primary Listing of OraSure Technologies.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • OraSure Technologies is good value based on assets compared to the US Medical Equipment industry average.
X
Value checks
We assess OraSure Technologies's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. OraSure Technologies has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is OraSure Technologies expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
17.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is OraSure Technologies expected to grow at an attractive rate?
  • OraSure Technologies's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • OraSure Technologies's earnings growth is expected to exceed the United States of America market average.
  • OraSure Technologies's revenue growth is positive but not above the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:OSUR Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:OSUR Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 17.7%
NasdaqGS:OSUR Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 6.4%
United States of America Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 22%
United States of America Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 7.9%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:OSUR Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:OSUR Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 198 25 1
2020-12-31 185 33 21 3
2019-12-31 173 32 14 3
NasdaqGS:OSUR Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 167 32 19
2018-12-31 180 39 20
2018-09-30 178 23 17
2018-06-30 176 20 15
2018-03-31 175 23 16
2017-12-31 166 28 31
2017-09-30 145 30 31
2017-06-30 135 30 31
2017-03-31 126 32 30
2016-12-31 123 25 20
2016-09-30 125 26 17
2016-06-30 123 36 12

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • OraSure Technologies's earnings are expected to grow by 17.7% yearly, however this is not considered high growth (20% yearly).
  • OraSure Technologies's revenue is expected to grow by 6.4% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:OSUR Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from OraSure Technologies Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:OSUR Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 0.39 0.39 0.39 1.00
2020-12-31 0.34 0.37 0.30 3.00
2019-12-31 0.23 0.23 0.23 3.00
NasdaqGS:OSUR Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 0.31
2018-12-31 0.33
2018-09-30 0.29
2018-06-30 0.25
2018-03-31 0.27
2017-12-31 0.52
2017-09-30 0.53
2017-06-30 0.55
2017-03-31 0.53
2016-12-31 0.35
2016-09-30 0.31
2016-06-30 0.22

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if OraSure Technologies will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess OraSure Technologies's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
OraSure Technologies has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has OraSure Technologies performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare OraSure Technologies's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • OraSure Technologies has delivered over 20% year on year earnings growth in the past 5 years.
  • OraSure Technologies's 1-year earnings growth is less than its 5-year average (17.5% vs 42.1%)
  • OraSure Technologies's earnings growth has not exceeded the US Medical Equipment industry average in the past year (17.5% vs 31.9%).
Earnings and Revenue History
OraSure Technologies's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from OraSure Technologies Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:OSUR Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 167.49 19.26 59.27 16.55
2018-12-31 180.04 20.40 58.13 16.25
2018-09-30 178.29 17.41 58.93 16.02
2018-06-30 175.85 15.08 59.20 15.39
2018-03-31 175.29 16.39 58.37 14.47
2017-12-31 166.38 30.95 57.85 13.37
2017-09-30 144.88 30.83 59.71 10.03
2017-06-30 135.04 31.31 58.95 10.00
2017-03-31 126.22 29.72 57.44 9.64
2016-12-31 122.80 19.72 58.01 9.75
2016-09-30 125.08 17.14 57.96 10.76
2016-06-30 122.69 12.37 61.23 10.09
2016-03-31 121.72 10.50 62.46 10.10
2015-12-31 119.72 8.17 61.06 11.17
2015-09-30 116.02 0.90 62.81 12.13
2015-06-30 114.00 0.57 61.03 12.59
2015-03-31 110.02 1.13 62.30 12.37
2014-12-31 106.46 -4.61 65.27 11.66
2014-09-30 106.55 4.25 65.90 9.85
2014-06-30 103.38 1.22 65.39 9.53
2014-03-31 101.31 -6.60 66.52 9.46
2013-12-31 98.94 -11.19 68.72 10.33
2013-09-30 92.32 -23.27 67.98 11.10
2013-06-30 89.76 -23.81 67.48 11.43
2013-03-31 88.04 -22.09 65.23 11.85
2012-12-31 87.82 -15.12 59.91 11.94
2012-09-30 89.36 -9.13 54.64 12.54
2012-06-30 88.96 -10.62 50.57 15.09

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • OraSure Technologies has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • OraSure Technologies used its assets less efficiently than the US Medical Equipment industry average last year based on Return on Assets.
  • OraSure Technologies has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess OraSure Technologies's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
OraSure Technologies has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is OraSure Technologies's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up OraSure Technologies's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • OraSure Technologies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • OraSure Technologies's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of OraSure Technologies's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 155.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from OraSure Technologies Company Filings, last reported 2 months ago.

NasdaqGS:OSUR Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 280.51 5.49 146.99
2018-12-31 283.38 0.00 156.57
2018-09-30 276.75 0.00 150.34
2018-06-30 265.17 0.00 145.32
2018-03-31 258.72 0.00 143.49
2017-12-31 258.08 0.00 154.06
2017-09-30 249.51 0.00 160.14
2017-06-30 229.41 0.00 160.23
2017-03-31 208.83 0.00 139.63
2016-12-31 185.85 0.00 119.12
2016-09-30 176.48 0.00 119.34
2016-06-30 168.79 0.00 113.44
2016-03-31 163.02 0.00 102.25
2015-12-31 159.44 0.00 101.32
2015-09-30 160.00 0.00 108.19
2015-06-30 159.85 0.00 91.41
2015-03-31 155.83 0.00 89.49
2014-12-31 158.70 0.00 97.87
2014-09-30 160.92 0.00 98.86
2014-06-30 160.32 0.00 80.27
2014-03-31 154.71 0.00 84.19
2013-12-31 161.15 0.00 93.19
2013-09-30 154.89 0.00 82.59
2013-06-30 154.55 0.00 76.96
2013-03-31 159.92 0.00 79.28
2012-12-31 170.32 0.00 87.89
2012-09-30 174.78 0.00 89.42
2012-06-30 98.84 7.04 23.27
  • OraSure Technologies's level of debt (0.5%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 0.5% today).
  • Debt is well covered by operating cash flow (2417.4%, greater than 20% of total debt).
  • Unable to confirm if the interest payments on OraSure Technologies's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess OraSure Technologies's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. OraSure Technologies has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is OraSure Technologies's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from OraSure Technologies dividends.
If you bought $2,000 of OraSure Technologies shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate OraSure Technologies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate OraSure Technologies's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:OSUR Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
United States of America Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 24 Stocks 1.2%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2011 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:OSUR Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as OraSure Technologies has not reported any payouts.
  • Unable to verify if OraSure Technologies's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of OraSure Technologies's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as OraSure Technologies has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess OraSure Technologies's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can OraSure Technologies afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. OraSure Technologies has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of OraSure Technologies's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Steve Tang
COMPENSATION $2,099,594
AGE 57
TENURE AS CEO 1.2 years
CEO Bio

Dr. Stephen S. Tang, also known as Steve, Ph.D. has been President and Chief Executive Officer at OraSure Technologies, Incorporation since April 01, 2018. Dr. Tang has been Chief Executive Officer and President of University City Science Center since January 2008. Dr. Tang has a wealth of professional experience in academia, professional services and private industry. Most notably, he is the first president in the Science Center's 45-year history to have not only led a company through venture funding and an initial public offering, but to also served as a senior executive with a large life sciences company as it acquired and integrated smaller start-ups. He served as General Manager and Group Vice President for Life Science at Olympus America Inc. from 2006 to 2008 and as Vice President of Life Science Business Development from 2005 to 2006. He joined Olympus in 2005. He served as President and Chief Executive Officer of Millennium Cell Inc. from June 2000 to March 19, 2004 and served as its Acting Chief Financial Officer since February 14, 2003. From January 1996 to June 2000, Dr. Tang served as Vice President and Vice President and Managing Director of the global pharmaceutical and healthcare practice for the management consulting firm A.T. Kearney, Inc., a wholly-owned subsidiary of Electronic Data Systems, Inc., where he directed global business development and marketing. Dr. Tang's extensive business experience and in particular his experience in the life sciences industry and with strategic and business development matters. He served as a Co-Leader, Vice President and Co- Managing Director of the global chemical and environmental practice of Gemini Consulting, Inc., a wholly-owned subsidiary of Cap Gemini. Prior to that, he served as President and Founder of Tangent Technologies, a technical consulting firm to chemical, pharmaceutical and biotechnology companies and senior research engineer and Assistant Director of Lehigh University's Center of Molecular Bioscience and Biotechnology. He served as the Chairman of OraSure Technologies, Inc. since November 14, 2016 until April 01, 2018. He has been a Director of University City Science Center since June 2010, OraSure Technologies, Inc. since April 6, 2011 and Greater Philadelphia Chamber of Commerce since October 2011. He serves as a Director of Neuro Diagnostic Devices, Inc. He serves as Member of the Innovation Advisory Board at United States Department of Commerce. He served as a Director of Millennium Cell Inc. from June 2000 to March 19, 2004. Dr. Tang received his B.S. in Chemistry from College of William and Mary, an M.S. and Ph.D. in Chemical Engineering from Lehigh University and an MBA from Wharton School of Business at University of Pennsylvania.

CEO Compensation
  • Steve's compensation has increased by more than 20% in the past year whilst earnings grew less than 20%.
  • Steve's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the OraSure Technologies management team in years:

1.8
Average Tenure
57
Average Age
  • The average tenure for the OraSure Technologies management team is less than 2 years, this suggests a new team.
Management Team

Steve Tang

TITLE
President
COMPENSATION
$2M
AGE
57
TENURE
1.2 yrs

Roberto Cuca

TITLE
CFO & Principal Accounting Officer
COMPENSATION
$1M
AGE
50
TENURE
1 yrs

Jack Jerrett

TITLE
Senior VP
COMPENSATION
$973K
AGE
59
TENURE
18.6 yrs

Tony Zezzo

TITLE
Executive VP & Business Unit Leader of Infectious Disease
COMPENSATION
$1M
AGE
64
TENURE
2.4 yrs

Brian Smith

TITLE
Vice Chairman & EVP of Innovation - DNA Genotek
COMPENSATION
$979K
AGE
59
TENURE
1.8 yrs

Mike Reed

TITLE
Senior VP of R&D and Chief Science Officer
COMPENSATION
$779K
AGE
49
TENURE
3.2 yrs

Jeanne Mell

TITLE
Vice President of Corporate Communications
TENURE
0.8 yrs

Nancy McLane

TITLE
Senior Vice President of Operations

Kathy Weber

TITLE
Executive VP & Business Unit Leader of Molecular Solutions
AGE
51
TENURE
6.6 yrs

David Rappaport

TITLE
Senior Vice President of Business Development
TENURE
1.2 yrs
Board of Directors Tenure

Average tenure and age of the OraSure Technologies board of directors in years:

3.3
Average Tenure
59
Average Age
  • The tenure for the OraSure Technologies board of directors is about average.
Board of Directors

Mike Celano

TITLE
Chairman of the Board
COMPENSATION
$506K
AGE
59
TENURE
1.2 yrs

Steve Tang

TITLE
President
COMPENSATION
$2M
AGE
57
TENURE
8.2 yrs

Ronny Lancaster

TITLE
Independent Director
COMPENSATION
$170K
AGE
66
TENURE
16.1 yrs

Eamonn Hobbs

TITLE
Independent Director
COMPENSATION
$157K
AGE
59
TENURE
3.3 yrs

Aradhana Sarin

TITLE
Independent Director
COMPENSATION
$562K
AGE
43
TENURE
1.3 yrs

Chuck Patrick

TITLE
Independent Director
COMPENSATION
$169K
AGE
63
TENURE
13.4 yrs

Mara Aspinall

TITLE
Independent Director
COMPENSATION
$157K
AGE
56
TENURE
2 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by OraSure Technologies insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
14. May 19 Buy Stephen Tang Individual 14. May 19 14. May 19 1,000 $8.56 $8,560
14. May 19 Buy Jack Jerrett Individual 13. May 19 13. May 19 10,000 $8.55 $85,487
14. May 19 Buy Roberto Cuca Individual 10. May 19 10. May 19 10,000 $9.04 $90,314
29. Aug 18 Sell Charles Patrick Individual 27. Aug 18 27. Aug 18 -8,000 $16.29 $-130,320
X
Management checks
We assess OraSure Technologies's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. OraSure Technologies has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Here's What OraSure Technologies, Inc.'s (NASDAQ:OSUR) P/E Ratio Is Telling Us

Check out our latest analysis for OraSure Technologies How Do I Calculate A Price To Earnings Ratio? … The formula for price to earnings is: Price to Earnings Ratio = Share Price ÷ Earnings per Share (EPS) Or for OraSure Technologies: P/E of 27.18 = $8.54 ÷ $0.31 (Based on the year to March 2019.) Is A High Price-to-Earnings Ratio Good? … NasdaqGS:OSUR Price Estimation Relative to Market, June 17th 2019 Its relatively low P/E ratio indicates that OraSure Technologies shareholders think it will struggle to do as well as other companies in its industry classification.

Simply Wall St -

Have Insiders Been Buying OraSure Technologies, Inc. (NASDAQ:OSUR) Shares?

As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.' Check out our latest analysis for OraSure Technologies The Last 12 Months Of Insider Transactions At OraSure Technologies Over the last year, we can see that the biggest insider sale was by the Independent Director, Charles Patrick, for US$130k worth of shares, at about US$16.29 per share. … OraSure Technologies Insiders Bought Stock Recently Over the last three months, we've seen significant insider buying at OraSure Technologies. … Insider Ownership of OraSure Technologies For a common shareholder, it is worth checking how many shares are held by company insiders.

Simply Wall St -

Estimating The Intrinsic Value Of OraSure Technologies, Inc. (NASDAQ:OSUR)

Using the most recent financial data, we'll take a look at whether the stock is fairly priced by estimating the company's future cash flows and discounting them to their present value. … Generally we assume that a dollar today is more valuable than a dollar in the future, so we need to discount the sum of these future cash flows to arrive at a present value estimate: 10-year free cash flow (FCF) estimate 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 Levered FCF ($, Millions) $25.40 $26.60 $27.68 $28.69 $29.65 $30.60 $31.53 $32.46 $33.39 $34.34 Growth Rate Estimate Source Analyst x1 Analyst x1 Est @ 4.04% Est @ 3.65% Est @ 3.37% Est @ 3.18% Est @ 3.05% Est @ 2.95% Est @ 2.88% Est @ 2.84% Present Value ($, Millions) Discounted @ 8.29% $23.45 $22.68 $21.79 $20.86 $19.91 $18.97 $18.05 $17.16 $16.30 $15.48 Present Value of 10-year Cash Flow (PVCF)= $194.65m "Est" = FCF growth rate estimated by Simply Wall St After calculating the present value of future cash flows in the intial 10-year period, we need to calculate the Terminal Value, which accounts for all future cash flows beyond the first stage. … Terminal Value (TV) = FCF2029 × (1 + g) ÷ (r – g) = US$34m × (1 + 2.7%) ÷ (8.3% – 2.7%) = US$634m Present Value of Terminal Value (PVTV) = TV / (1 + r)10 = $US$634m ÷ ( 1 + 8.3%)10 = $285.79m The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is $480.44m.

Simply Wall St -

If You Had Bought OraSure Technologies (NASDAQ:OSUR) Shares Five Years Ago You'd Have Made 51%

During the five years of share price growth, OraSure Technologies moved from a loss to profitability. … Given that the company made a profit three years ago, but not five years ago, it is worth looking at the share price returns over the last three years, too. … Indeed, the OraSure Technologies share price has gained 43% in three years.

Simply Wall St -

What You Must Know About OraSure Technologies, Inc.'s (NASDAQ:OSUR) Beta Value

(NASDAQ:OSUR), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Beta is a widely used metric to measure a stock's exposure to market risk (volatility). … The first thing to understand about beta is that the beta of the overall market is one.

Simply Wall St -

A Closer Look At OraSure Technologies, Inc.'s (NASDAQ:OSUR) Uninspiring ROE

By way of learning-by-doing, we'll look at ROE to gain a better understanding of OraSure Technologies, Inc. … OraSure Technologies has a ROE of 7.2%, based on the last twelve months. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Want To Invest In OraSure Technologies, Inc. (NASDAQ:OSUR) Today? Read This First

Growth expectations for OraSure Technologies, Inc. … (NASDAQ:OSUR) are high, but many investors are starting to ask whether its last close at $11.07 can still be rationalized by the future potential. … OraSure Technologies is poised for significantly high earnings growth in the near future

Simply Wall St -

At US$11.56, Is OraSure Technologies, Inc. (NASDAQ:OSUR) Worth Looking At Closely?

received a lot of attention from a substantial price increase on the NASDAQGS over the last few months. … With many analysts covering the stock, we may expect any price-sensitive announcements have already been factored into the stock’s share price? … Let’s examine OraSure Technologies’s valuation and outlook in more detail to determine if there’s still a bargain opportunity

Simply Wall St -

How Much Are OraSure Technologies, Inc. (NASDAQ:OSUR) Insiders Taking Off The Table?

So shareholders might well want to know whether insiders have been buying or selling shares in OraSure Technologies, Inc. … But logic dictates you should pay some attention to whether insiders are buying or selling shares. … The Last 12 Months Of Insider Transactions At OraSure Technologies.

Simply Wall St -

Does OraSure Technologies, Inc. (NASDAQ:OSUR) Have A Good P/E Ratio?

We'll look at OraSure Technologies, Inc.'s (NASDAQ:OSUR) P/E ratio and reflect on what it tells us about the company's share price. … OraSure Technologies has a P/E ratio of 34.49, based on the last twelve months. … Price to Earnings Ratio = Price per Share ÷ Earnings per Share (EPS)

Simply Wall St -

Company Info

Description

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Its principal products include OraQuick ADVANCE HIV-1/2, OraQuick HIV–1/2, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV, OraQuick Ebola, OraQuick Zika, OraSure QuickFlu Rapid Flu A&B test, OraSure, Oragene DX, Oragene DNA, Oragene RNA, ORAcollect DX, ORAcollect DNA, Performagene, OMNIgene GUT, OMNIgene SPUTUM, OMNIgene VAGINAL, OMNIgene ORAL, GenoFIND, Hemagene, PrepIT, Intercept, MICRO-PLATE DOA assays, Intercept i2, homogeneous DOA assays, and professional and over-the-counter cryosurgical systems. In addition, the company manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. Further, it provides medical devices for the removal of benign skin lesions by cryosurgery or freezing; immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot confirmatory test for confirming positive HIV-1 test; and Q.E.D. rapid point-of-care saliva alcohol test. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. OraSure Technologies, Inc. was founded in 2000 and is based in Bethlehem, Pennsylvania.

Details
Name: OraSure Technologies, Inc.
OSUR
Exchange: NasdaqGS
Founded: 2000
$548,529,125
62,050,806
Website: http://www.orasure.com
Address: OraSure Technologies, Inc.
220 East First Street,
Bethlehem,
Pennsylvania, 18015,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS OSUR Common Stock Nasdaq Global Select US USD 17. Nov 1986
DB EP3 Common Stock Deutsche Boerse AG DE EUR 17. Nov 1986
Number of employees
Current staff
Staff numbers
398
OraSure Technologies employees.
Industry
Health Care Supplies
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/19 23:41
End of day share price update: 2019/06/19 00:00
Last estimates confirmation: 2019/06/17
Last earnings filing: 2019/05/09
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.